Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1183-1188

  Meissner, H Cody ^a,j   Groothuis, Jessie R ^b   Rodriguez, William J ^c   Welliver, Robert C ^d   Hogg, Geoff ^e   Gray, Peter H ^f   Loh, Richard ^g   Simoes, Eric A F ^h   Sly, Peter ^g   Miller, Ann K ⁱ   Nichols, Alice I ^i,k   Jorkasky, Diane K ⁱ   Everitt, Daniel E ⁱ   Thompson, Kathleen A ⁱ  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL OF BUFFALO   (United States)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f South Brisbane   (Australia)

^g PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ SmithKline Beecham   (United States)

^j TUFTS MEDICAL CENTER   (United States)

^k Hawthorne Research and Consulting   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FELVIZUMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTRIBUTION VOLUME; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOPROPHYLAXIS; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG DYSPLASIA; MALE; MULTICENTER STUDY; PREMATURITY; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOSIS; VIRUS INFECTION; VIRUS NEUTRALIZATION;

EID: 0032905244     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1183     Document Type: Article

References (19)

1. Beal, S. L., and L. B. Sheiner. 1980. The NONMEM system. Am. Stat. 34:118.
2. Beal, S. L., and L. B. Sheiner. 1978 and 1985. NONMEM users guide, parts I to VI. University of California, San Francisco.
3. Davis, C. B., T. W. Hepburn, J. J. Urbanski, D. C. Kwok, T. K. Hart, D. J. Herzyk, S. G. Demuth, M. Leland, and G. R. Rhodes. 1995. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab. Dispos. 23: 1028-1036.
4. Everitt, D. E., C. B. Davis, K. Thompson, R. DiCicco, B. Ilson, S. G. Demuth, D. J. Herzyk, and D. K. Jorkasky. 1996. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J. Infect. Dis. 174:463-469.
5. Green, T. P., and B. L. Mirkin. 1984. Clinical pharmacokinetics: pediatric considerations, p. 269-282. In L. Z. Bennet, N. Massoud, and J. G. Gambertoglio (ed.), Pharmacokinetic basis for drug treatment. Raven Press, New York, N.Y.
6. Groothuis, J. R., E. A. F. Simoes, J. J. Levin, et al. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and children. N. Engl. J. Med. 329:1524-1530.
7. Hall, C. B. 1994. Prospects for a respiratory syncytial virus vaccine. Science 265:1393-1394.
8. Heilman, C. A. 1990. Respiratory syncytial and parainfiuenza viruses. J. Infect. Dis. 161:402-406.
9. IMPACT-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from RSV infection in high-risk infants. Pediatrics 102:531-537.
10. Meissner, H. C., R. C. Welliver, S. A. Chartrand, D. R. Fulton, W. J. A. Rodriguez, and J. R. Groothuis. 1996. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr. Infect. Dis. J. 15:1059-1068.
11. Meissner, H. C., and J. R. Groothuis. 1997. Immunoprophylaxis and control of RSV disease. Pediatrics 100:260-263.
12. Olmsted, R. A., N. Elango, G. A. Prince, B. R. Murphy, P. R. Johnson, B. Moss, and P. Collins. 1986. Expression of the F glycoprotein of respiratory syncytial virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. USA 83: 7462-7466.
13. PREVENT Study Group. 1997. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99.
14. Siber, G. R., J. Leszczynski, V. Pena-Cruz, C. Ferren-Gardner, R. Anderson, V. G. Hemming, E. E. Walsh, J. Burns, K. McIntosh, R. Gonin, and L. J. Anderson. 1992. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. 165:456-463.
15. Stott, E. J., G. Taylor, L. A. Ball, K. Anderson, K.K.-Y. Young, A. M. Q. King, and G. W. Wertz. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:3855-3861.
16. Subramanian, K. N. S., L. E. Weisman, T. Rhodes, R. Ariagno, P. J. Sanchez, J. Steichen, L. B. Givner, T. L. Jennings, F. H. Top, Jr., D. Carlin, and E. Connor. 1998. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17:110-115.
17. Taylor, G., E. J. Stott, M. Hughes, and A. P. Collins. 1984. Respiratory syncytial virus in mice. Infect. Immun. 43:649-655.
18. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:756-758.
19. Wyde, P. R., D. K. Moore, T. Hepburn, C. L. Silverman, T. G. Porter, M. Gross, G. Taylor, S. G. Demuth, and S. B. Dillon. 1995. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:543-549.